Oric Pharmaceuticals, Inc. (ORIC) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 44 days, typically, give or take 8 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Mon, Nov 16, 2026after close 47 8-K
Q2 FY2026Mon, Aug 3, 2026after close 34 8-K
Q1 FY2026Mon, May 4, 2026after close 34 8-K
Q4 FY2025Mon, Feb 23, 2026after close 54 8-K
Q3 FY2025Thu, Nov 13, 2025after close 44 8-K
Q2 FY2025Tue, Aug 12, 2025after close 43 8-K
Q1 FY2025Mon, May 5, 2025after close 35 8-K
Q4 FY2024Tue, Feb 18, 2025after close 49 8-K

What they guided beta

Q3 FY2026 "Announced Redwood-1 global Phase 3 registrational trial in 1L EGFR atypical NSCLC, with initiation expected in 1H 2027 Cash and investments of approximately $345 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout from first Phase 3 trial for rinzimetostat" exhibit
Q3 FY2026 "Presented preclinical data at ESMO Congress 2026 highlighting potential advantages of targeting PRC2 via EED over EZH2, including that prostate cancer cells that rapidly developed resistance to the EZH2 inhibitor mevrometostat acquired an EZH2 mutation against which the potency of the EED inhibitor rinzimetostat was maintained." exhibit
Q3 FY2026 "The company expects its cash and investments to fund the operating plan into 2H 2028." exhibit
Q2 FY2026 "ORIC ® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1 Anticipate rinzimetostat program update in 2H 2026 and enozertinib clinical updates in 2H 2026 ahead of potential initiation of a registrational trial Cash and investments of approximately $388 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint rea" exhibit
Q2 FY2026 "Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments totaled $387.6 million as of June 30, 2026, which includes $59.9 million in net proceeds raised from healthcare specialist funds during the first quarter under the ATM (at-the-market) program." exhibit
Q2 FY2026 "The company expects its cash and investments to fund the operating plan into 2H 2028." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ORIC
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ORIC

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

ORIC earnings date badge

HTML

<a href="https://veritasdata.dev/company/ORIC/"><img src="https://veritasdata.dev/embed/ORIC.svg" alt="ORIC earnings date" width="240" height="56"></a>

Markdown

[![ORIC earnings date](https://veritasdata.dev/embed/ORIC.svg)](https://veritasdata.dev/company/ORIC/)

Script

<script async src="https://veritasdata.dev/embed/ORIC.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ORIC"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.